electroCore, Inc. (ECOR)
NASDAQ: ECOR · Real-Time Price · USD
4.820
+0.170 (3.66%)
At close: May 12, 2025, 4:00 PM
4.820
0.00 (0.00%)
After-hours: May 12, 2025, 4:52 PM EDT
electroCore Revenue
electroCore had revenue of $6.72M in the quarter ending March 31, 2025, with 23.44% growth. This brings the company's revenue in the last twelve months to $26.46M, up 41.54% year-over-year. In the year 2024, electroCore had annual revenue of $25.18M with 57.09% growth.
Revenue (ttm)
$26.46M
Revenue Growth
+41.54%
P/S Ratio
1.39
Revenue / Employee
$362,438
Employees
73
Market Cap
34.67M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 25.18M | 9.15M | 57.09% |
| Dec 31, 2023 | 16.03M | 7.44M | 86.57% |
| Dec 31, 2022 | 8.59M | 3.14M | 57.62% |
| Dec 31, 2021 | 5.45M | 1.96M | 55.93% |
| Dec 31, 2020 | 3.50M | 1.11M | 46.25% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 63.92B |
| AbbVie | 57.37B |
| AstraZeneca | 54.98B |
| Novartis AG | 53.22B |
| Eli Lilly and Company | 49.00B |
| Novo Nordisk | 43.92B |
ECOR News
- 4 days ago - electroCore, Inc. (ECOR) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 5 days ago - electroCore Announces First Quarter 2025 Financial Results - GlobeNewsWire
- 10 days ago - electroCore Completes Acquisition of NeuroMetrix, Gaining Access to its Quell Platform, Creating Significant Player in Non-Invasive Bioelectronic Technologies - GlobeNewsWire
- 11 days ago - electroCore's Truvaga™ Now Works with the Apple Health app - GlobeNewsWire
- 12 days ago - electroCore to Announce First Quarter March 31, 2025 Financial Results on Wednesday, May 7, 2025 - GlobeNewsWire
- 25 days ago - gammaCore Non-Invasive Vagus Nerve Stimulation (nVNS) Shown to be Effective in Treating Concussive Symptoms Associated with Mild Traumatic Brain Injuries - GlobeNewsWire
- 26 days ago - electroCore to Participate at the Planet MicroCap Showcase - GlobeNewsWire
- 5 weeks ago - electroCore Named One of The Americas' Fastest Growing Companies by the Financial Times - GlobeNewsWire